Advances in donor-derived cell-free DNA monitoring for solid organ transplantation
Blood tests detecting transplant rejection signals could help doctors catch problems earlier and better protect donated organs.
This narrative review synthesizes evidence on dd-cfDNA monitoring technologies (NGS and digital PCR) for detecting allograft rejection after solid organ transplantation, emphasizing analytical and preanalytical factors affecting clinical performance. The authors conclude dd-cfDNA is a valuable surveillance adjunct but requires standardized reporting frameworks and prospective outcome studies before broader clinical adoption.
What the study was
- Study design
- Narrative review
- Population
- Solid organ transplant recipients
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Frontiers in Immunology
Why it surfaced
Comprehensive review of dd-cfDNA assay landscape; directly relevant to liquid biopsy/cfDNA watchlist. Scores as STANDARD — review design limits novelty, and watchlist alignment is peripheral (transplant, not cancer screening).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.